US Patent 7566719 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
Patent 7566719 was granted and assigned to Enanta Pharmaceuticals on July, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 15 Sep, 2023
Golden AI
Edits made to:
Article (+144 characters)
Article
Patent abstract
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07566719 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors US Patent 7566719 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
Infobox
Patent Number
0756671900
Patent Number
756671900
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 30 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075667190
Date of Patent
July 28, 2009
0Patent Application Number
120434210
Date Filed
March 6, 2008
0Official Website
Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075667190
Date of Patent
July 28, 2009
0Patent Application Number
120434210
Date Filed
March 6, 2008
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07566719 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07566719
Date of patent
July 28, 2009
Patent application number
12043421
Date Filed
March 6, 2008
Patent primary examiner
Find more entities like US Patent 7566719 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
